Ultragenyx Pharmaceuticals has acquired privately held GeneTx BioTherapeutics for $75 million, convinced an experimental therapy the two companies are developing has promise for treating a rare neurogenetic condition known as Angelman syndrome.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,